Prospects for a dengue virus vaccine

Stephen S. Whitehead; Joseph E. Blaney; Anna P. Durbin; Brian R. Murphy

doi:10.1038/nrmicro1690

Prospects for a dengue virus vaccine

Stephen S. Whitehead, Joseph E. Blaney, Anna P. Durbin, Brian R. Murphy

Bloomberg School of Public Health

Research output: Contribution to journal › Review article › peer-review

418 Scopus citations

Abstract

The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

Original language	English (US)
Pages (from-to)	518-528
Number of pages	11
Journal	Nature Reviews Microbiology
Volume	5
Issue number	7
DOIs	https://doi.org/10.1038/nrmicro1690
State	Published - Jul 2007

ASJC Scopus subject areas

Microbiology
General Immunology and Microbiology
Infectious Diseases

Access to Document

10.1038/nrmicro1690

Cite this

@article{6489ccbb86cc41a5b479be095c42c672,

title = "Prospects for a dengue virus vaccine",

abstract = "The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.",

author = "Whitehead, {Stephen S.} and Blaney, {Joseph E.} and Durbin, {Anna P.} and Murphy, {Brian R.}",

note = "Funding Information: Support for S.S.W., J.E.B., A.P.D. (in part) and B.R.M. is provided by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.",

year = "2007",

month = jul,

doi = "10.1038/nrmicro1690",

language = "English (US)",

volume = "5",

pages = "518--528",

journal = "Nature Reviews Microbiology",

issn = "1740-1526",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Prospects for a dengue virus vaccine

AU - Whitehead, Stephen S.

AU - Blaney, Joseph E.

AU - Durbin, Anna P.

AU - Murphy, Brian R.

N1 - Funding Information: Support for S.S.W., J.E.B., A.P.D. (in part) and B.R.M. is provided by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.

PY - 2007/7

Y1 - 2007/7

N2 - The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

AB - The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

UR - http://www.scopus.com/inward/record.url?scp=34250365710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250365710&partnerID=8YFLogxK

U2 - 10.1038/nrmicro1690

DO - 10.1038/nrmicro1690

M3 - Review article

C2 - 17558424

AN - SCOPUS:34250365710

SN - 1740-1526

VL - 5

SP - 518

EP - 528

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

IS - 7

ER -

Prospects for a dengue virus vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this